跳过至主要内容
翻译进行中 — 您的语言版本正在准备中，目前内容以英语显示。
返回讨论

诺华首席执行官瓦桑特·纳拉西姆汉论改造一家250年历史的公司

Business
全球
开始于 February 17, 2026

a16z general partner Jorge Conde talks with Vasant Narasimhan, CEO of Novartis International, about transforming a 250-year-old conglomerate into a pure play medicines company and unlocking $180 billion of value in the process. They cover Novartis's platform technologies: cell and gene therapies, RNA medicines, and radioligand therapies. They also discuss AI in drug discovery, the rise of China as a biotech competitor, and what Vasant looks for when evaluating startup partnerships, including ...

来源文章

添加陈述 分析 0/5
Need to find a specific claim? Search all statements.
🗳️ Join the conversation
5 条陈述待投票 • Your perspective shapes the analysis
📊 Progress to Consensus Analysis Need: 7+ participants, 20+ votes, 3+ votes per statement
Participants 0/7
Statements (7+ recommended) 5/7
Total Votes 0/20
💡 Progress updates live here. Final readiness is confirmed when all three requirements are met.

Your votes count

No account needed — your votes are saved and included in the consensus analysis. Create an account to track your voting history and add statements.

CLAIM 发布者 will • Feb 17, 2026
Partnerships with startups should focus on long-term collaboration, as short-term gains may lead to unsustainable practices in the biotech industry.

翻译待处理

Vote options for this statement: agree, disagree, or unsure
💬 查看讨论
Be first to respond
Vote to see results
CLAIM 发布者 will • Feb 17, 2026
AI's role in drug discovery at Novartis could streamline research processes, but ethical concerns about data use must be addressed.

翻译待处理

Vote options for this statement: agree, disagree, or unsure
💬 查看讨论
Be first to respond
Vote to see results
CLAIM 发布者 will • Feb 17, 2026
The focus on high-value therapies may neglect affordable treatments, widening the gap in healthcare access for underserved populations.

翻译待处理

Vote options for this statement: agree, disagree, or unsure
💬 查看讨论
Be first to respond
Vote to see results
CLAIM 发布者 will • Feb 17, 2026
Emphasizing cell and gene therapies positions Novartis as a leader in biotech, essential for competing against rising players like China.

翻译待处理

Vote options for this statement: agree, disagree, or unsure
💬 查看讨论
Be first to respond
Vote to see results
CLAIM 发布者 will • Feb 17, 2026
Transforming Novartis into a pure play medicines company will drive innovation and significantly enhance patient care worldwide.

翻译待处理

Vote options for this statement: agree, disagree, or unsure
💬 查看讨论
Be first to respond
Vote to see results

💡 How This Works

  • • Add Statements: Post claims or questions (10-500 characters)
  • • Vote: Agree, Disagree, or Unsure on each statement
  • • Respond: Add detailed pro/con responses with evidence
  • • Consensus: After enough participation, analysis reveals opinion groups and areas of agreement

Society Speaks is open and independent. Your support keeps civic discussion free from advertising and commercial influence.

Support us